Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, MN, MA, CO, WA, OR, UT · listed May 12, 2009 → Jan 29, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:55 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:55 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:55 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 58 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Apr 20, 2026 D File 021-581106 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 29, 2026 D File 021-571607 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 1, 2025 D File 021-565407 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 1, 2025 D File 021-550457 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 7, 2025 D/A File 021-508253 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 6, 2024 D File 021-523384 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2024 D File 021-518643 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2024 D File 021-518633 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 9, 2024 D File 021-512771 | $0 | $0 | $0 Excludes standard compensation for officers and directors. | None listed on this filing |
| EDGAR ↗ | Apr 12, 2024 D File 021-510516 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 9, 2024 D/A File 021-496904 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 1, 2023 D File 021-498542 | $0 | $0 | $0 Excludes standard compensation for officers and directors. | None listed on this filing |
| EDGAR ↗ | Nov 30, 2023 D File 021-498408 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 29, 2023 D File 021-498398 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2022 D File 021-468515 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2022 D File 021-443568 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 19, 2022 D/A File 021-371987 | $0 | $0 | $0 Excludes standard compensation for officers and directors. | None listed on this filing |
| EDGAR ↗ | Dec 22, 2021 D File 021-426383 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2021 D File 021-426384 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 14, 2021 D File 021-413262 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 13, 2021 D File 021-406015 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 13, 2021 D File 021-406019 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 14, 2021 D File 021-402745 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 10, 2020 D File 021-382855 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 6, 2020 D File 021-377225 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 11, 2020 D File 021-368739 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 19, 2020 D File 021-363266 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 5, 2020 D File 021-359821 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 26, 2019 D File 021-349663 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 18, 2019 D File 021-342143 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 10, 2019 D File 021-339316 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 10, 2019 D File 021-339322 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 16, 2019 D File 021-337410 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 14, 2019 D File 021-332905 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 4, 2019 D File 021-329723 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 17, 2018 D File 021-319535 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 17, 2018 D File 021-319529 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 2, 2018 D File 021-309064 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 10, 2017 D File 021-296259 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 2, 2017 D File 021-285865 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 23, 2016 D/A File 021-253249 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 17, 2016 D File 021-269114 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | May 27, 2016 D File 021-263974 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 26, 2016 D File 021-263888 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 22, 2016 D/A File 021-253725 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 30, 2015 D File 021-254112 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 1, 2015 D File 021-248599 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 24, 2015 D/A File 021-197112 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 2, 2015 D File 021-243013 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 14, 2014 D/A File 021-214865 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 20, 2014 D File 021-219551 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 6, 2013 D File 021-207569 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 7, 2013 D File 021-204066 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 19, 2012 D File 021-175189 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 27, 2011 D File 021-166409 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 13, 2010 D File 021-151789 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 12, 2010 D File 021-141954 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 18, 2010 D File 021-130867 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Route 92 Medical, Inc. | Director | Apr 20, 2026 | D | $50,000,002 similar: $829,831–$9,999,998 | $50,000,002 | 11 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AIS VGP-6, LLC | Director Manager | Jan 29, 2026 | D | $15,623,844 similar: $500,000–$7,000,000 | $5,555,075 | 30 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Dec 1, 2025 | D | $46,735,000 similar: $1,100,015–$10,001,163 | $28,936,718 | 27 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Sparrow Pharmaceuticals, Inc. | Director | Jul 1, 2025 | D | $121,400,027 similar: $1,694,259–$16,000,000 | $61,841,225 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CARLSMED, INC. | Director | Feb 7, 2025 | D/A | $64,499,995 similar: $500,000–$7,000,000 | $64,499,995 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Sep 6, 2024 | D | $30,000,000 similar: $1,100,015–$10,001,163 | $18,633,332 | 8 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Route 92 Medical, Inc. | Director | Jul 12, 2024 | D | $50,398,458 similar: $829,831–$9,999,998 | $50,398,458 | 5 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AIS VGP-6, LLC | Director Manager | Jul 12, 2024 | D | $3,093,968 similar: $500,000–$7,000,000 | $3,093,968 | 13 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | NUVAIRA, INC. | Director | May 9, 2024 | D | $56,382 | $52,875 | 13 | No minimum reported |
| EDGAR ↗ | Sparrow Pharmaceuticals, Inc. | Director | Apr 12, 2024 | D | $15,251,730 similar: $1,694,259–$16,000,000 | $10,000,000 | 4 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CARLSMED, INC. | Director | Mar 21, 2024 | D | $52,499,996 similar: $500,000–$7,000,000 | $38,499,996 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Jan 9, 2024 | D/A | $6,131,309 similar: $1,100,015–$10,001,163 | $5,735,308 | 20 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | NUVAIRA, INC. | Director | Dec 1, 2023 | D | $17,251,125 similar: $829,831–$9,999,998 | $15,124,893 | 39 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AIS VGP-6, LLC | Director | Nov 30, 2023 | D | $5,731,477 similar: $500,000–$7,000,000 | $5,731,477 | 16 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Route 92 Medical, Inc. | Director | Nov 29, 2023 | D | $31,268,156 similar: $829,831–$9,999,998 | $31,268,156 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Nov 9, 2023 | D | $6,131,309 similar: $1,100,015–$10,001,163 | $5,000,000 | 5 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Ribon Therapeutics, Inc. | Director | Dec 22, 2022 | D | $25,000,000 similar: $2,000,000–$19,999,994 | $25,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CARLSMED, INC. | Director | Apr 27, 2022 | D | $29,999,990 similar: $2,000,000–$19,999,994 | $29,999,990 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NUVAIRA, INC. | Director | Jan 19, 2022 | D/A | $68,228,304 similar: $829,831–$9,999,998 | $31,337,640 | 49 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Highway 1 Medical, Inc. | Director | Dec 22, 2021 | D | $639,613 similar: $829,831–$9,999,998 | $639,613 | 3 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | El Camino Real Medical, Inc. | Director | Dec 22, 2021 | D | $319,806 similar: $829,831–$9,999,998 | $319,806 | 3 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Sep 14, 2021 | D | $7,500,000 similar: $1,100,015–$10,001,163 | $7,500,000 | 19 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | AIS VGP-6, LLC | Director | Jul 13, 2021 | D | $14,500,001 similar: $500,000–$7,000,000 | $11,900,004 | 16 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Route 92 Medical, Inc. | Director | Jul 13, 2021 | D | $61,000,001 similar: $829,831–$9,999,998 | $46,900,004 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Ribon Therapeutics, Inc. | Director | Jun 14, 2021 | D | $60,150,139 similar: $2,000,000–$19,999,994 | $25,150,140 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NUVAIRA, INC. | Director | Jan 15, 2021 | D/A | $58,228,304 similar: $829,831–$9,999,998 | $21,337,640 | 45 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Edgewise Therapeutics, Inc. | Director | Dec 10, 2020 | D | $95,000,000 similar: $2,000,000–$19,999,994 | $95,000,000 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Silverback Therapeutics, Inc. | Director | Oct 6, 2020 | D | $84,999,995 similar: $2,000,000–$19,999,994 | $84,999,995 | 31 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NUVAIRA, INC. | Director | Jul 29, 2020 | D | $49,999,997 similar: $829,831–$9,999,998 | $17,417,640 | 44 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Jun 11, 2020 | D | $7,200,001 similar: $1,100,015–$10,001,163 | $7,200,001 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Silverback Therapeutics, Inc. | Director | Mar 19, 2020 | D | $78,697,259 similar: $2,000,000–$19,999,994 | $31,754,277 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Swoop.com, Inc | Director | Feb 5, 2020 | D | $3,000,000 similar: $500,000–$7,000,000 | $3,000,000 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Edgewise Therapeutics, Inc. | Director | Sep 26, 2019 | D | $50,149,999 similar: $1,100,015–$10,001,163 | $25,074,998 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Cleave Biosciences, Inc. | Director | Jun 18, 2019 | D | $20,800,000 similar: $2,000,000–$19,999,994 | $11,970,369 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AIS VGP-6, LLC | Director | May 10, 2019 | D | $2,999,997 similar: $500,000–$7,000,000 | $2,999,997 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Route 92 Medical, Inc. | Director | May 10, 2019 | D | $12,999,994 similar: $829,831–$9,999,998 | $12,999,994 | 2 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Okami Medical, Inc. | Director | Apr 16, 2019 | D | $3,000,000 similar: $1,100,015–$10,001,163 | $3,000,000 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | NUVAIRA, INC. | Director | Feb 14, 2019 | D | $75,000,000 similar: $829,831–$9,999,998 | $25,000,004 | 20 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Ribon Therapeutics, Inc. | Director | Jan 4, 2019 | D | $65,000,000 similar: $2,000,000–$19,999,994 | $25,415,384 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Route 92 Medical, Inc. | Director | Aug 17, 2018 | D | $6,728,135 similar: $829,831–$9,999,998 | $4,728,135 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AIS VGP-6, LLC | Director | Aug 17, 2018 | D | $6,728,136 similar: $500,000–$7,000,000 | $4,728,136 | 16 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Inari Medical, Inc. | Director | Apr 2, 2018 | D | $27,000,000 similar: $829,831–$9,999,998 | $27,000,000 | 20 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Ribon Therapeutics, Inc. | Director | Oct 10, 2017 | D | $20,000,001 similar: $2,000,000–$19,999,994 | $20,000,001 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AIS VGP-6, LLC | Director | May 2, 2017 | D | $5,855,447 similar: $500,000–$7,000,000 | $5,855,447 | 20 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Ribon Therapeutics, Inc. | Director | Nov 23, 2016 | D/A | $23,500,000 similar: $2,000,000–$19,999,994 | $23,500,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cleave Biosciences, Inc. | Director | Aug 17, 2016 | D | $36,750,001 similar: $2,000,000–$19,999,994 | $25,950,003 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AIS VGP-6, LLC | Director | May 27, 2016 | D | $5,900,000 similar: $500,000–$7,000,000 | $5,900,000 | 16 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Route 92 Medical, Inc. | Director | May 26, 2016 | D | $5,900,000 similar: $2,000,000–$19,999,994 | $5,900,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | EFFECTOR THERAPEUTICS, INC. | Director | Feb 22, 2016 | D/A | $56,000,005 similar: $2,000,000–$19,999,994 | $56,000,005 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inari Medical, Inc. | Director | Dec 30, 2015 | D | $6,125,000 similar: $829,831–$9,999,998 | $6,125,000 | 5 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | EFFECTOR THERAPEUTICS, INC. | Director | Dec 23, 2015 | D | $45,000,005 similar: $2,000,000–$19,999,994 | $40,000,004 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Ribon Therapeutics, Inc. | Director | Dec 17, 2015 | D | $21,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Omada Health, Inc. | Director | Oct 1, 2015 | D | $48,666,531 similar: $829,831–$9,999,998 | $48,666,531 | 16 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | EFFECTOR THERAPEUTICS, INC. | Director | Jul 24, 2015 | D/A | $56,983,867 similar: $2,000,000–$19,999,994 | $36,206,089 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inari Medical, Inc. | Director | Jul 2, 2015 | D | $12,405,000 similar: $829,831–$9,999,998 | $12,405,000 | 24 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Sequent Medical, Inc. | Director | Nov 14, 2014 | D/A | $20,100,000 similar: $1,100,015–$10,001,163 | $20,100,000 | 20 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | EFFECTOR THERAPEUTICS, INC. | Director | Aug 14, 2014 | D/A | $56,983,867 similar: $2,000,000–$19,999,994 | $21,539,423 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Omada Health, Inc. | Director | Jun 20, 2014 | D | $23,000,000 similar: $829,831–$9,999,998 | $22,869,994 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Sequent Medical, Inc. | Director | Apr 3, 2014 | D | $20,000,000 similar: $1,100,015–$10,001,163 | $20,000,000 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | OncoMed Pharmaceuticals Inc | Director | Dec 6, 2013 | D | $22,249,996 similar: $2,000,000–$14,000,000 | $22,249,996 | 1 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Inari Medical, Inc. | Director | Oct 7, 2013 | D | $4,710,000 similar: $829,831–$9,999,998 | $4,710,000 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Sequent Medical, Inc. | Director | Mar 19, 2012 | D | $26,037,698 similar: $1,100,015–$10,001,163 | $26,037,051 | 24 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Inari Medical, Inc. | Director | Sep 27, 2011 | D | $6,650,000 similar: $500,000–$7,000,000 | $1,650,000 | 8 similar: 2–14 | $1 similar: $5,000–$50,000 |
| EDGAR ↗ | LUTONIX INC | Director | Dec 13, 2010 | D | $45,000,005 similar: $2,000,000–$19,999,994 | $10,000,001 | 23 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Sequent Medical, Inc. | Director | May 12, 2010 | D | $15,624,996 similar: $1,100,015–$10,001,163 | $15,624,996 | 10 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Sequent Medical, Inc. | Director | Mar 18, 2010 | D | $1,000,000 similar: $1,100,015–$10,001,163 | $1,000,000 | 3 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Sequent Medical, Inc. | Director | May 12, 2009 | D | $2,500,000 similar: $1,100,015–$10,001,163 | $2,500,000 | 14 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (6 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Jonathan Root. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Jonathan Root appears on a new Form D, or when a court case or SEC action is matched to them. See plans →